Literature DB >> 11085945

PrPSc-like prion protein peptide inhibits the function of cellular prion protein.

D R Brown1.   

Abstract

Mice lacking expression of the prion protein are protected against infection with prion disease. Neurodegeneration in prion disease requires the formation of the abnormal isoform of the prion protein (PrP(Sc)) from host prion protein. Therefore expression of normal host prion protein is necessary for prion disease. In the present investigation, it was demonstrated that PrP(Sc) and a peptide resembling PrP(Sc), PrP106-126, both bind to cellular prion protein at amino acid residues 112-119. Interaction between PrP106-126 and the prion protein strips the prion protein from cells. Direct interaction of PrP106-126 with the prion protein was found to make cells more susceptible to copper toxicity, inhibited copper uptake into cells and inhibited the superoxide dismutase-like activity of the prion protein. Direct inhibition of prion protein function by PrP(Sc) may be necessary for neurodegeneration in prion disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085945      PMCID: PMC1221483     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  40 in total

1.  Consequences of manganese replacement of copper for prion protein function and proteinase resistance.

Authors:  D R Brown; F Hafiz; L L Glasssmith; B S Wong; I M Jones; C Clive; S J Haswell
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

2.  Normal prion protein has an activity like that of superoxide dismutase.

Authors:  D R Brown; B S Wong; F Hafiz; C Clive; S J Haswell; I M Jones
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

3.  Differential release of cellular and scrapie prion proteins from cellular membranes by phosphatidylinositol-specific phospholipase C.

Authors:  N Stahl; D R Borchelt; S B Prusiner
Journal:  Biochemistry       Date:  1990-06-05       Impact factor: 3.162

4.  Fibrils from brains of cows with new cattle disease contain scrapie-associated protein.

Authors:  J Hope; L J Reekie; N Hunter; G Multhaup; K Beyreuther; H White; A C Scott; M J Stack; M Dawson; G A Wells
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

5.  Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy.

Authors:  B W Caughey; A Dong; K S Bhat; D Ernst; S F Hayes; W S Caughey
Journal:  Biochemistry       Date:  1991-08-06       Impact factor: 3.162

6.  Identification of a protein that purifies with the scrapie prion.

Authors:  D C Bolton; M P McKinley; S B Prusiner
Journal:  Science       Date:  1982-12-24       Impact factor: 47.728

7.  Prion protein peptides: optimal toxicity and peptide blockade of toxicity.

Authors:  D R Brown
Journal:  Mol Cell Neurosci       Date:  2000-01       Impact factor: 4.314

8.  Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel.

Authors:  R C Moore; I Y Lee; G L Silverman; P M Harrison; R Strome; C Heinrich; A Karunaratne; S H Pasternak; M A Chishti; Y Liang; P Mastrangelo; K Wang; A F Smit; S Katamine; G A Carlson; F E Cohen; S B Prusiner; D W Melton; P Tremblay; L E Hood; D Westaway
Journal:  J Mol Biol       Date:  1999-10-01       Impact factor: 5.469

9.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.

Authors:  H Büeler; M Fischer; Y Lang; H Bluethmann; H P Lipp; S J DeArmond; S B Prusiner; M Aguet; C Weissmann
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

10.  Novel proteinaceous infectious particles cause scrapie.

Authors:  S B Prusiner
Journal:  Science       Date:  1982-04-09       Impact factor: 47.728

View more
  15 in total

Review 1.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Transgenesis applied to transmissible spongiform encephalopathies.

Authors:  Jean-Luc Vilotte; Hubert Laude
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

3.  Polymorphisms of SPRN (shadow of prion protein homology) in three breeds of sheep in China.

Authors:  Xaioli Zhang; Xiangmei Zhou; Tianjian Ding; Wenqiang Gan; Lifeng Yang; Xiaomin Yin; Deming Zhao
Journal:  Virus Genes       Date:  2012-02-26       Impact factor: 2.332

Review 4.  Redox control of prion and disease pathogenesis.

Authors:  Neena Singh; Ajay Singh; Dola Das; Maradumane L Mohan
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

5.  Molecular features of the copper binding sites in the octarepeat domain of the prion protein.

Authors:  Colin S Burns; Eliah Aronoff-Spencer; Christine M Dunham; Paula Lario; Nikolai I Avdievich; William E Antholine; Marilyn M Olmstead; Alice Vrielink; Gary J Gerfen; Jack Peisach; William G Scott; Glenn L Millhauser
Journal:  Biochemistry       Date:  2002-03-26       Impact factor: 3.162

6.  Metal imbalance and compromised antioxidant function are early changes in prion disease.

Authors:  Alana M Thackray; Robert Knight; Stephen J Haswell; Raymond Bujdoso; David R Brown
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

Review 7.  Molecular advances in understanding inherited prion diseases.

Authors:  David R Brown
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

8.  Gold complexes inhibit the aggregation of prion neuropeptides.

Authors:  Xuesong Wang; Lei He; Cong Zhao; Weihong Du; Jun Lin
Journal:  J Biol Inorg Chem       Date:  2013-08-28       Impact factor: 3.358

9.  Mapping molecular association networks of nervous system diseases via large-scale analysis of published research.

Authors:  Xiaojun Hu; Dangzhi Zhao; Andreas Strotmann
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin.

Authors:  Victoria Last; Alun Williams; Dirk Werling
Journal:  BMC Neurosci       Date:  2012-08-28       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.